Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA: 688076)

Jiangsu Sinopep-Allsino Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	555.22	749.08	399.96	591.88	69.71	58.1
Trading Asset Securities	185	-	43.01	87.13	80	-
Cash & Short-Term Investments	740.22	749.08	442.98	679.01	149.71	58.1
Cash Growth	81.55%	69.10%	-34.76%	353.54%	157.70%	-69.78%
Accounts Receivable	489.14	297.26	251.29	143.37	109.12	84.18
Other Receivables	4.43	3.27	1.19	1.05	5.05	2.91
Receivables	493.57	300.53	252.48	144.41	114.17	87.09
Inventory	436.05	377.17	323.48	250.82	185	115.3
Other Current Assets	52.02	67.98	33.53	29.86	39.03	33.25
Total Current Assets	1,722	1,495	1,052	1,104	487.91	293.73
Property, Plant & Equipment	1,506	1,405	988.47	706.55	613.74	654.9
Long-Term Investments	154.36	117.5	94.5	-	-	-
Goodwill	156.34	156.34	156.34	160.92	162.2	162.2
Other Intangible Assets	108.17	112.1	98.18	88.57	87.11	85.07
Long-Term Deferred Tax Assets	69.48	46.65	28.13	16.63	26.5	31.17
Long-Term Deferred Charges	94.73	41.03	38.77	15.66	12.02	12.21
Other Long-Term Assets	204.48	173.84	65.44	34.46	6.11	5.23
Total Assets	4,015	3,547	2,522	2,127	1,396	1,245
Accounts Payable	128.48	141.93	87.61	72.36	24.49	20.05
Accrued Expenses	66.52	86.14	48.49	43.99	32.98	25.23
Short-Term Debt	817.6	546.02	318.73	77.27	177.95	126.13
Current Portion of Long-Term Debt	60.45	40.08	-	-	32	20.3
Current Portion of Leases	5.41	5.29	1.47	3.64	-	-
Current Income Taxes Payable	26.07	11.47	5.37	-	12.85	6.01
Current Unearned Revenue	36.71	8.39	6.85	26.17	13.34	10.21
Other Current Liabilities	112.39	134.01	82.8	51.96	88.6	126.37
Total Current Liabilities	1,254	973.34	551.32	275.4	382.21	334.3
Long-Term Debt	248.86	286.49	-	-	37.95	59.01
Long-Term Leases	15.98	17.18	-	2.74	-	-
Long-Term Unearned Revenue	27.73	31.46	35.32	21.74	4.4	1.9
Long-Term Deferred Tax Liabilities	9.38	10.16	10.77	4.26	4.99	5.71
Other Long-Term Liabilities	39.31	39.31	-	14	-	4.63
Total Liabilities	1,595	1,358	597.41	318.14	429.55	405.54
Common Stock	214.93	213.18	213.18	213.18	159.89	159.89
Additional Paid-In Capital	1,446	1,341	1,319	1,318	641.03	635.41
Retained Earnings	637.26	495.37	374.95	277.82	162.43	38.99
Comprensive Income & Other	96.35	120.23	3.33	2.2	-	-
Total Common Equity	2,394	2,170	1,910	1,811	963.34	834.29
Minority Interest	26.22	19.04	14.66	-2.61	2.68	4.69
Shareholders' Equity	2,421	2,189	1,925	1,809	966.02	838.98
Total Liabilities & Equity	4,015	3,547	2,522	2,127	1,396	1,245
Total Debt	1,148	895.07	320.19	83.65	247.89	205.43
Net Cash (Debt)	-408.08	-145.98	122.79	595.36	-98.18	-147.34
Net Cash Growth	-	-	-79.38%	-	-	-
Net Cash Per Share	-1.84	-0.68	0.58	3.10	-0.61	-0.91
Filing Date Shares Outstanding	214.93	213.18	213.18	213.18	159.89	159.89
Total Common Shares Outstanding	214.93	213.18	213.18	213.18	159.89	159.89
Working Capital	468.21	521.43	501.15	828.71	105.7	-40.56
Book Value Per Share	11.14	10.18	8.96	8.50	6.03	5.22
Tangible Book Value	2,130	1,902	1,656	1,562	714.04	587.02
Tangible Book Value Per Share	9.91	8.92	7.77	7.33	4.47	3.67
Buildings	521.96	504.29	476.24	376.08	339.12	248.51
Machinery	1,320	1,123	652.13	529	435.18	248.3
Construction In Progress	160.93	185.96	180.11	34.85	9.88	277.3

Source: S&P Capital IQ. Standard template. Financial Sources.